BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
Healthcare
$3.07 -6.54%
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
52W Low $2.25High $8.40
Volume 0.09M
Average 0.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$9.94M
FY 2025 · Annual
-59.4% YoYInvesting Cash Flow
-$2.10M
FY 2025 · Annual
Financing Cash Flow
-$1.12M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.41M) | (7.11M) | (8.48M) | 31.88M | (6.58M) |
| Depreciation & Amortization | 283.79K | 243.42K | 395.32K | 293.22K | 381.02K |
| Deferred Income Tax | (689.36K) | 0 | 0 | 0 | 3.99M |
| Stock-Based Compensation | 403.02K | 4.9M | 6.67M | 0 | 0 |
| Change in Working Capital | 515.9K | 7.59K | (3.54M) | (12.01M) | (3.98M) |
| Accounts Receivables | (288.25K) | 262.93K | (11.33M) | (93.78M) | 4.43M |
| Inventory | 209.35K | (135.18K) | (263.45K) | (1.17M) | (1.05M) |
| Accounts Payables | (19.49K) | (77.14K) | 821.57K | 4.42M | (1.5M) |
| Other Working Capital | 614.3K | (43.03K) | 8.06M | 78.52M | (5.86M) |
| Other Non-Cash Items | 788.99K | 322.58K | 1.46M | 4.31M | 16.12M |
| Operating Cash Flow | (109.44K) | (1.64M) | (3.5M) | 24.48M | 9.94M |
| Capital Expenditures | (42.85K) | (469.48K) | (105.33K) | (426.57K) | (3.35M) |
| Acquisitions (Net) | 35K | 0 | (105K) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (1.25M) | 1.25M |
| Investing Cash Flow | (7.85K) | (469.48K) | (210.33K) | (1.68M) | (2.1M) |
| Debt Repayment | 232.42K | 547.71K | 797.06K | (849.4K) | (1.17M) |
| Common Stock Issued | 125K | 50K | 2.38M | 642.62K | 48.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (391.79K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 357.42K | 597.71K | 3.18M | (206.78K) | (1.12M) |
| Effect of Forex Changes | 0 | 1.97M | 0 | 0 | 0 |
| Net Change in Cash | 240.13K | 431.8K | (532.73K) | 22.59M | 6.72M |
| Free Cash Flow | (152.29K) | (2.11M) | (3.6M) | 24.05M | 6.59M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$6.6M
+ D&A$381.0K
+ Stock-Based Comp$0
+ Deferred Tax$4.0M
- Working Capital-$4.0M
+ Other Non-Cash$16.1M
= Operating Cash Flow$9.9M
- Capex-$3.4M
= Free Cash Flow$6.6M
Analysis
FY2025 free cash flow is $6.6M. FCF conversion is -100.1% of net income. Operating cash flow was $9.9M, with capex of -$3.4M. The largest bridge item is Other Non-Cash at $16.1M.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-1 | S-1 filing | Sep 18, 2026 | |
| 8-K | Current report | Sep 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
Does BSEM generate free cash flow?
BioStem Technologies, Inc. (BSEM) generated $6.59M of free cash flow in fiscal 2025.
How much operating cash flow does BSEM produce?
Operating cash flow was $9.94M, before capital expenditures of $3.35M.
Continue the stock analysis
Jump to another research area for this company.